BOK Financial’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.72M | Buy |
8,111
+361
| +5% | +$70.8K | 0.02% | 352 |
|
|
2026
Q1 | $1.52M | Sell |
7,750
-12,653
| -62% | -$2.46M | 0.02% | 368 |
|
|
2025
Q4 | $3.54M | Sell |
20,403
-6,940
| -25% | -$1.26M | 0.05% | 237 |
|
|
2025
Q3 | $5.21M | Sell |
27,343
-33
| -0.1% | -$5.86K | 0.08% | 205 |
|
|
2025
Q2 | $4.92M | Sell |
27,376
-14,124
| -34% | -$2.45M | 0.08% | 202 |
|
|
2025
Q1 | $7.02M | Sell |
41,500
-2,104
| -5% | -$346K | 0.12% | 146 |
|
|
2024
Q4 | $6.62M | Sell |
43,604
-38
| -0.1% | -$5.91K | 0.11% | 163 |
|
|
2024
Q3 | $6.64M | Buy |
43,642
+216
| +0.5% | +$32.3K | 0.12% | 159 |
|
|
2024
Q2 | $5.94M | Sell |
43,426
-4,206
| -9% | -$576K | 0.11% | 175 |
|
|
2024
Q1 | $6.42M | Sell |
47,632
-24,249
| -34% | -$3.15M | 0.12% | 177 |
|
|
2023
Q4 | $9.91M | Sell |
71,881
-12,074
| -14% | -$1.59M | 0.19% | 109 |
|
|
2023
Q3 | $10.9M | Buy |
83,955
+14,267
| +20% | +$1.9M | 0.24% | 91 |
|
|
2023
Q2 | $9.8M | Sell |
69,688
-65
| -0.1% | -$8.96K | 0.2% | 113 |
|
|
2023
Q1 | $9.87M | Sell |
69,753
-2,279
| -3% | -$326K | 0.21% | 111 |
|
|
2022
Q4 | $11.3M | Buy |
72,032
+2,325
| +3% | +$334K | 0.21% | 109 |
|
|
2022
Q3 | $8.55M | Buy |
69,707
+28,128
| +68% | +$3.7M | 0.17% | 128 |
|
|
2022
Q2 | $5.53M | Sell |
41,579
-6,301
| -13% | -$859K | 0.11% | 189 |
|
|
2022
Q1 | $6.55M | Sell |
47,880
-1,863
| -4% | -$260K | 0.11% | 190 |
|
|
2021
Q4 | $8.61M | Buy |
49,743
+4,122
| +9% | +$627K | 0.13% | 167 |
|
|
2021
Q3 | $6.63M | Buy |
+45,621
| New | +$6.68M | 0.11% | 190 |
|
|
2021
Q1 | $4.66M | Sell |
36,329
-6,378
| -15% | -$786K | 0.08% | 225 |
|
|
2020
Q4 | $5.09M | Buy |
42,707
+25,738
| +152% | +$3.14M | 0.1% | 200 |
|
|
2020
Q3 | $1.94M | Sell |
16,969
-7,176
| -30% | -$848K | 0.04% | 328 |
|
|
2020
Q2 | $2.75M | Buy |
24,145
+866
| +4% | +$91.9K | 0.06% | 265 |
|
|
2020
Q1 | $1.87M | Sell |
23,279
-6,488
| -22% | -$672K | 0.05% | 297 |
|
|
2019
Q4 | $3.18M | Sell |
29,767
-349
| -1% | -$36.4K | 0.07% | 269 |
|
|
2019
Q3 | $3.22M | Sell |
30,116
-682
| -2% | -$70K | 0.08% | 258 |
|
|
2019
Q2 | $3.14M | Buy |
30,798
+2,198
| +8% | +$211K | 0.08% | 264 |
|
|
2019
Q1 | $2.57M | Buy |
28,600
+34
| +0.1% | +$2.95K | 0.06% | 301 |
|
|
2018
Q4 | $2.38M | Sell |
28,566
-341
| -1% | -$32K | 0.07% | 287 |
|
|
2018
Q3 | $3.12M | Sell |
28,907
-42
| -0.1% | -$4.61K | 0.08% | 287 |
|
|
2018
Q2 | $3.18M | Buy |
28,949
+3,470
| +14% | +$361K | 0.09% | 275 |
|
|
2018
Q1 | $2.56M | Buy |
25,479
+5,690
| +29% | +$583K | 0.07% | 304 |
|
|
2017
Q4 | $1.95M | Buy |
19,789
+6,794
| +52% | +$644K | 0.05% | 355 |
|
|
2017
Q3 | $1.22M | Sell |
12,995
-184
| -1% | -$19.5K | 0.04% | 443 |
|
|
2017
Q2 | $1.47M | Sell |
13,179
-162
| -1% | -$17.1K | 0.05% | 389 |
|
|
2017
Q1 | $1.31M | Buy |
13,341
+193
| +1% | +$18.4K | 0.04% | 426 |
|
|
2016
Q4 | $1.21M | Buy |
13,148
+4,247
| +48% | +$366K | 0.04% | 421 |
|
|
2016
Q3 | $753K | Buy |
8,901
+1,757
| +25% | +$148K | 0.02% | 539 |
|
|
2016
Q2 | $582K | Buy |
7,144
+1,261
| +21% | +$96K | 0.02% | 555 |
|
|
2016
Q1 | $420K | Buy |
5,883
+1,909
| +48% | +$128K | 0.02% | 620 |
|
|
2015
Q4 | $283K | Buy |
3,974
+625
| +19% | +$42K | 0.01% | 710 |
|
|
2015
Q3 | $206K | Buy |
3,349
+33
| +1% | +$2.31K | 0.01% | 773 |
|
|
2015
Q2 | $241K | Buy |
+3,316
| New | +$245K | 0.01% | 754 |
|
Other funds holding DGX
EIG
BOK Financial's DGX Position: Q2 2026 in Review
BOK Financial increased its Quest Diagnostics (DGX) stake by 4.7% in Q2 2026, buying an estimated $70.8K and bringing the position to 8,111 shares worth $1.72M. The position accounts for 0.02% of the portfolio, ranked #352.
BOK Financial first reported a position in DGX in Q2 2015 and has held it in 44 quarters since. The position peaked at $11.3M in Q4 2022. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- BOK Financial held 8,111 shares of Quest Diagnostics worth $1.72M as of Q2 2026.
- BOK Financial bought 361 Quest Diagnostics shares in Q2 2026, an estimated $70.8K.
- Quest Diagnostics made up 0.02% of BOK Financial's portfolio in Q2 2026, its #352 holding.
- BOK Financial first reported a position in Quest Diagnostics in Q2 2015 and has held it in 44 quarters since.
- BOK Financial's Quest Diagnostics position peaked at $11.3M in Q4 2022.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.